# Study of Epratuzumab in Systemic Lupus Erythematosus

> **NCT00383513** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 29 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Epratuzumab

## Key facts

- **NCT ID:** NCT00383513
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2012-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383513, "Study of Epratuzumab in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00383513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*